Navigation Links
Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
Date:10/29/2009

by the use of forward-looking terminology such as "expect," "plans," "anticipates," "will," "expects," "goal" or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of IDX184, or any other product candidate and any future clinical trials involving our product candidates and expectations with respect to additional milestone payments, future royalty payments, funding of operations and future cash balances. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 3
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
4. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
5. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
6. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
9. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
10. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
11. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
(Date:3/3/2015)... , March 3, 2015 NASA astronaut ... launch this month to spend a year living and working ... satellite interviews from 5:30 to 7 a.m. EDT Monday, March ... as he completes the final weeks of his ... a video on NASA Television highlighting his mission training and ...
(Date:3/3/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced several new ... in North America , the Middle ... "Bidding activity in 2015 continues to be robust" said Derek ... for bidding in 2014, we are pleased to see the bidding ... organization,s renewed focus on select market segments where we can add ...
(Date:3/3/2015)... , March 3, 2015  Neurocrine Biosciences, Inc. ... Kevin Gorman , President and Chief Executive Officer of ... Healthcare Conference in Miami.   The live ... ET (7:15am PT).  The presentation will be webcast and ... http://www.neurocrine.com .   Listeners are encouraged to ...
Breaking Biology Technology:Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... Bulletin Board:,NTRZ), a world leader in stabilized rice ... it has appointed Olga Hernandez-Longan [45],to the position ... with,his previously announced intentions, has retired as CFO, ... capacity., Ms. Hernandez-Longan has over 20 years ...
... higher revenue due to Roche milestone -, BRISBANE, Calif., ... results from operations for the third,quarter and nine months ended ... quarter of 2008 of $12.5 million, or $0.32 per share,compared ... share, in the third,quarter of 2007., Dan Welch, Chairman, ...
... Nov. 6 ViroPharma Incorporated,(Nasdaq: VPHM ) ... officer of ViroPharma, will present at the Rodman ... ET on Wednesday, November,12, 2008. The conference is ... ViroPharma also announced that Colin Broom, vice ...
Cached Biology Technology:NutraCea Appoints New Chief Financial Officer 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 8InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 9ViroPharma to Present at Three November Healthcare Conferences 2
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2
... Oct. 27, 2009 UT Southwestern Medical Center patient ... receive the newest generation of a mechanical device designed to ... awaits a heart transplant. Called a left-ventricular assist device ... pump blood throughout the body. For Mr. LeBlanc, it will ...
... 45 percent of blood, normally take the shape of circular ... sometimes deform into an asymmetrical slipper shape. A team ... might be responsible for this deformation, as well as how ... help understand the mechanisms involved in arterial disease and other ...
... nest? Early in development infants of many species experience ... presence of their mother to start exploring the wider ... the brain during that turning point. Based on ... strength of attachments in many speciesincluding the conundrum of ...
Cached Biology News:UT Southwestern patient first in North Texas to receive newest-generation heart failure device 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 3Changes in brain chemicals mark shifts in infant learning 2Changes in brain chemicals mark shifts in infant learning 3
MAb to Mouse MHC Class I H-2Kd...
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
... Perhaps sheer in-house demand is causing shortages ... your precious antibody. This can cause unwanted ... • Receive royalties for your hard work ... let us build it up and market ...
Biology Products: